Search results for "Neoplastic"

showing 10 items of 2901 documents

Adverse Reactions to Anticancer Drugs in the Oral Cavity

2018

The development, testing, and adoption into clinical practice of anticancer medications have revolutionized cancer care over the past decades. A better understanding of the biology of cancer has translated into development of novel systemic agents, as well a more effective use of older chemotherapy agents. As a consequence, cancer mortality continues to decrease. However, greater cure and disease control rates come at a price of an increased risk of adverse effects, which often affects the mouth and related structures including the oral mucosa, salivary glands, jawbones, and cranial nerves. Oral mucositis, hyposalivation, dysgeusia, and osteonecrosis of the jaw (ONJ) are some examples of th…

MouthArticle SubjectGeneral Immunology and Microbiologybusiness.industrylcsh:RMEDLINElcsh:MedicineAntineoplastic AgentsGeneral MedicineOral cavityBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyEditorialText miningHumansMedicineMouth DiseasesbusinessBioMed Research International
researchProduct

Effect of zinc on oropharyngeal mucositis in children with acute leukemia undergoing chemotherapy

2020

Background Oropharyngeal mucositis (OM) is one of the main side-effects of oncological therapy. There is no treatment to prevent its occurrence, but some zinc-based therapies have been proven to help in decreasing its intensity. The objective of this study was to determine the effect of zinc in OM in children with acute leukemia in the early stages of oncological treatment. Material and Methods This quasi-experimental study evaluated OM in 2 groups (control group: conventional hospital management, and experimental group: administration of 50 mg of zinc gluconate daily plus conventional hospital management). OM severity was recorded at a two-month follow-up. Results Forty-nine patients (26 i…

MucositisOropharyngeal mucositismedicine.medical_specialtyAdolescentLymphoblastic Leukemiamedicine.medical_treatmentchemistry.chemical_elementAntineoplastic AgentsZincGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineMucositisHumansChildGeneral DentistryStomatitisAcute leukemiaChemotherapyPain scoreLeukemiabusiness.industryResearchMean age030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in Dentistrymedicine.diseaseZincOtorhinolaryngologychemistryUNESCO::CIENCIAS MÉDICASFemaleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Poisson convergence on continuous time branching random walks and multistage carcinogenesis.

1982

A theorem for Poisson convergence on realizations of two-dimensional Branching Random Walks with an underlying continuous time Markov Branching Process is proved. This result can be used to gain an approximation for the number of cells having sustained a certain deficiency after a long time in multistage carcinogenesis.

Multistage carcinogenesisTime FactorsMarkov chainApplied MathematicsPoisson distributionRandom walkAgricultural and Biological Sciences (miscellaneous)Models BiologicalCombinatoricsBranching (linguistics)symbols.namesakeCell Transformation NeoplasticBranching random walkModeling and SimulationNeoplasmsConvergence (routing)symbolsApplied mathematicsAnimalsHumansMathematicsMathematicsBranching processJournal of mathematical biology
researchProduct

Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies

2021

Hypericumis a widely present plant, and extracts of its leaves, flowers, and aerial elements have been employed for many years as therapeutic cures for depression, skin wounds, and respiratory and inflammatory disorders. Hypericum also displays an ample variety of other biological actions, such as hypotensive, analgesic, anti-infective, anti-oxidant, and spasmolytic abilities. However, recent investigations highlighted that this species could be advantageous for the cure of other pathological situations, such as trigeminal neuralgia, as well as in the treatment of cancer. This review focuses on the in vitro and in vivo antitumor effects of St. John’s Wort (Hypericum perforatum), its derivat…

MyeloidAngiogenesisDrug Evaluation PreclinicalReviewPharmacologylcsh:Chemistrychemistry.chemical_compoundhyperforinDrug InteractionsMyeloid CellsLymphocyteslcsh:QH301-705.5SpectroscopybiologyapoptosisleukemiaHypericum perforatumGeneral MedicineComputer Science ApplicationsHypericinLeukemiamedicine.anatomical_structurephotodynamic therapyHematologic NeoplasmsHypericumHypericumSt. John’s wortlymphomaCatalysisInorganic ChemistryStructure-Activity Relationshipmultidrug resistanceIn vivoCell Line TumormedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyCell ProliferationPlant Extractsbusiness.industryOrganic Chemistry<i>Hypericum</i>biology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicApoptosis; Hyperforin; Hypericin; Hypericum; Leukemia; Lymphoma; Mul-tidrug resistance; Photodynamic therapy; St. John’s wort; Animals; Antineoplastic Agents Phytogenic; Apoptosis; Cell Line Tumor; Cell Proliferation; Drug Evaluation Preclinical; Drug Interactions; Drug Resistance Neoplasm; Hematologic Neoplasms; Humans; Hypericum; Lymphocytes; Myeloid Cells; Plant Extracts; Structure-Activity RelationshipHyperforinchemistrylcsh:Biology (General)lcsh:QD1-999Drug Resistance NeoplasmhypericinbusinessInternational Journal of Molecular Sciences
researchProduct

Intravenous Busulfan for Autologous Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: a Survey of 952 Patients on Behalf of th…

2014

Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67 +/- 2%, 53 +/- 2%, and 40 +/- 2%, respectively. The non-relapse mortality rate at 2 years was 7 +/- 1%. Five patients died from ve…

MyeloidMale[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyBone Marrow Transplantation/mortalitymedicine.medical_treatmentLeukemia Myeloid Acute/therapyHematopoietic stem cell transplantationAntineoplastic Agents Alkylating/administration & dosageLeukemia Myeloid Acute/mortalityGastroenterologyHSAC ONCAutologous stem-cell transplantationHematopoietic Stem Cell Transplantation/mortalityInfusions IntravenousBone Marrow TransplantationAcute leukemiaSurvival Rate/trendsTransplantation Autologous/mortalityLeukemiaData CollectionHematopoietic Stem Cell Transplantation[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedAlkylating3. Good healthEuropeSurvival RateLeukemia Myeloid AcuteLeukemiaFemaleIntravenousAutologousmedicine.drugAdultBusulfan/administration & dosageInfusionsmedicine.medical_specialtyAdolescentCyclophosphamideAntineoplastic AgentsAcuteTransplantation AutologousEurope/epidemiologyData Collection/methodsYoung AdultInternal medicinemedicineHumansAntineoplastic Agents AlkylatingBusulfanSurvival rateAgedRetrospective StudiesTransplantationbusiness.industrySettore MED/15medicine.diseaseTransplantationAdolescent; Adult; Aged; Antineoplastic Agents Alkylating; Bone Marrow Transplantation; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions Intravenous; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Autologous; Young Adult; Data CollectionImmunologybusinessBusulfan
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition

2020

Abstract The interaction of menin (MEN1) and MLL (MLL1, KMT2A) is a dependency and provides a potential opportunity for treatment of NPM1-mutant (NPM1mut) and MLL-rearranged (MLL-r) leukemias. Concomitant activating driver mutations in the gene encoding the tyrosine kinase FLT3 occur in both leukemias and are particularly common in the NPM1mut subtype. In this study, transcriptional profiling after pharmacological inhibition of the menin-MLL complex revealed specific changes in gene expression, with downregulation of the MEIS1 transcription factor and its transcriptional target gene FLT3 being the most pronounced. Combining menin-MLL inhibition with specific small-molecule kinase inhibitors…

NPM1Transcription GeneticImmunologyApoptosisBiochemistryMiceRandom AllocationMice Inbred NODCell Line TumorProto-Oncogene Proteinshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsGene expressionmedicineAnimalsHumansMEN1PhosphorylationMyeloid Ecotropic Viral Integration Site 1 ProteinProtein Kinase InhibitorsneoplasmsbiologyGene Expression Regulation LeukemicKinaseNuclear ProteinsMyeloid leukemiaDrug SynergismHistone-Lysine N-MethyltransferaseCell BiologyHematologymedicine.diseaseCoculture TechniquesNeoplasm ProteinsLeukemia Myeloid AcuteLeukemiaKMT2Afms-Like Tyrosine Kinase 3biology.proteinCancer researchNucleophosminProtein Processing Post-TranslationalTyrosine kinaseMyeloid-Lymphoid Leukemia ProteinBlood
researchProduct

Nalidixic acid-resistant V79 cells with reduced DNA topoisomerase II activity and amplification prone phenotype

1992

Spontaneously nalidixic acid-resistant lines (NAr lines) were selected from a V79 Chinese hamster cell line and phenotypically characterized. NAr lines showed an increased doubling time, a higher number of spontaneous SCE, and more interestingly, decreased DNA topoisomerase II activity. These lines were also cross-resistant to the eukaryotic topoisomerase II inhibitors etoposide and adriamycin, but showed the same level of sensitivity as the parental line to the DNA topoisomerase I inhibitor camptothecin. NAr lines were cross-resistant to other drugs, such as PALA, MTX and MPA, resistance to which has been shown to arise by amplification of the target genes. This last feature, together with…

Nalidixic acidCell SurvivalHealth Toxicology and MutagenesisDrug ResistanceAntineoplastic AgentsBiologyCell LineNalidixic Acidchemistry.chemical_compoundCricetulusCricetinaeGeneticsmedicineAnimalsTopoisomerase II InhibitorsMolecular BiologyGeneEtoposideEtoposideCell NucleusMesocricetusTopoisomeraseGene AmplificationNucleic Acid HybridizationDNADNA topoisomerase II activityMolecular biologyDNA Topoisomerases Type IIPhenotypeDNA Topoisomerases Type IchemistryDoxorubicinbiology.proteinTopoisomerase-II InhibitorSister Chromatid ExchangeDNACamptothecinmedicine.drugMutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
researchProduct

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by int…

2020

International audience; Introduction The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.Materials and methods Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival.Results The median overall sur…

Neoplasm Residualmedicine.medical_treatmentGenes BRCA2FIGO Stage IIICGenes BRCA1Platinum CompoundsCarcinoma Ovarian EpithelialCohort Studies0302 clinical medicineAscitic FluidOverall survivalPeritoneal Lavage030212 general & internal medicineOvarian NeoplasmsUnivariate analysisCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedPrognosisDebulkingNeoadjuvant Therapy3. Good healthSurvival RateOncology030220 oncology & carcinogenesisFemaleTaxoidsFranceOmentumCohort studymedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic Agents[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsInterval debulking surgeryNeoadjuvant chemotherapyPelvis03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerOvarian cancerMedian follow-upmedicineHumansNeoplasm InvasivenessAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryRetrospective cohort studymedicine.diseaseSurgery[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMultivariate AnalysisLymph Node Excision[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSurgeryLymphadenectomyLymph NodesOvarian cancerbusinessEuropean Journal of Surgical Oncology
researchProduct

Cancer chemotherapy in the older cancer patient.

2009

This article reviews the principles of systemic cancer treatment in older individuals. These include: assessment of physiologic age with a comprehensive geriatric assessment (CGA), adjustment of chemotherapy doses to the patient's renal function, and prevention of myelotoxicity with hemopoietic growth factors. Other complications that become more common with age include mucositis, peripheral neuropathy and cardiomyopathy. Two chronic complications of chemotherapy become more common with age, including myelodysplasia and chronic cardiomyopathy. The goal of systemic cancer treatment in the older person should include prolongation of active life-expectancy and compression of morbidity in addit…

Nephrologymedicine.medical_specialtyAgingSettore MED/06 - Oncologia MedicaUrologymedicine.medical_treatmentCardiomyopathySystemic treatmentAntineoplastic AgentsKidneyMedical OncologyPatient Care PlanningElderlyLife ExpectancyInternal medicineNeoplasmsmedicineMucositisChemotherapyHumansIntensive care medicineGeriatric AssessmentCancerAgedAged 80 and overChemotherapybusiness.industryKidney metabolismCancermedicine.diseasePeripheral neuropathyTreatment OutcomeOncologyCompression of morbiditybusinessUrologic oncology
researchProduct